LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Search

Myriad Genetics Inc

Closed

SectorHealthcare

6.52 -1.06

Overview

Share price change

24h

Current

Min

6.47

Max

6.55

Key metrics

By Trading Economics

Income

303M

-27M

Sales

-7.4M

206M

Profit margin

-13.32

Employees

2,700

EBITDA

305M

-9.8M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+12.67% upside

Market Stats

By TradingEconomics

Market Cap

-131M

630M

Previous open

7.58

Previous close

6.52

News Sentiment

By Acuity

50%

50%

152 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Myriad Genetics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

24 Dec 2025, 21:41 UTC

Acquisitions, Mergers, Takeovers

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

24 Dec 2025, 14:57 UTC

Acquisitions, Mergers, Takeovers

Accenture to Acquire Cabel Industry from Fibonacci Group

25 Dec 2025, 23:42 UTC

Market Talk

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25 Dec 2025, 23:40 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25 Dec 2025, 00:20 UTC

Acquisitions, Mergers, Takeovers

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24 Dec 2025, 22:22 UTC

Acquisitions, Mergers, Takeovers

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 Dec 2025, 21:26 UTC

Acquisitions, Mergers, Takeovers

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 Dec 2025, 19:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 Dec 2025, 19:35 UTC

Market Talk

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 Dec 2025, 19:09 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

24 Dec 2025, 19:09 UTC

Market Talk
Acquisitions, Mergers, Takeovers

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 Dec 2025, 19:06 UTC

Market Talk

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

24 Dec 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

24 Dec 2025, 17:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

24 Dec 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 Dec 2025, 17:08 UTC

Acquisitions, Mergers, Takeovers

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 Dec 2025, 16:53 UTC

Acquisitions, Mergers, Takeovers

Nike Climb Boosts Dow, S&P 500 -- WSJ

24 Dec 2025, 16:31 UTC

Market Talk
Acquisitions, Mergers, Takeovers

ServiceNow Gets Top-Tier Asset and Talent With Armis Buy -- Market Talk

24 Dec 2025, 16:28 UTC

Acquisitions, Mergers, Takeovers

Lam Research Is at All-Time Highs. Its CEO Just Sold $27 Million Worth of Stock. -- Barrons.com

24 Dec 2025, 16:17 UTC

Market Talk

Dollar Stable as U.S. Layoffs Remain at Bay -- Market Talk

24 Dec 2025, 15:33 UTC

Acquisitions, Mergers, Takeovers

Nike Shares Get a Lift After Apple's Tim Cook Doubles His Personal Stake -- WSJ

24 Dec 2025, 15:30 UTC

Acquisitions, Mergers, Takeovers

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 Dec 2025, 15:19 UTC

Acquisitions, Mergers, Takeovers

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 Dec 2025, 14:49 UTC

Acquisitions, Mergers, Takeovers

Mexico's Ollamani Sells Stake in Azteca Stadium

24 Dec 2025, 14:19 UTC

Market Talk

U.S. Natural Gas Futures Move Lower After Big Jump -- Market Talk

24 Dec 2025, 14:08 UTC

Acquisitions, Mergers, Takeovers

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 Dec 2025, 14:06 UTC

Market Talk

Oil Futures Edge Up on Geopolitical Risk Premium -- Market Talk

24 Dec 2025, 13:24 UTC

Market Talk

Canada's Economy Needs More Help Amid Dismal GDP Report -- Market Talk

24 Dec 2025, 12:59 UTC

Acquisitions, Mergers, Takeovers

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 Dec 2025, 12:51 UTC

Acquisitions, Mergers, Takeovers

Disney Could Be the Real Winner from the Warner Takeover Battle. Here's Why. -- Barrons.com

Peer Comparison

Price change

Myriad Genetics Inc Forecast

Price Target

By TipRanks

12.67% upside

12 Months Forecast

Average 7.38 USD  12.67%

High 9 USD

Low 4 USD

Based on 5 Wall Street analysts offering 12 month price targets forMyriad Genetics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

2

Buy

2

Hold

1

Sell

Technical Score

By Trading Central

N/A / 7.55Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

152 / 374 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
help-icon Live chat